Chartmaster
2 일 전
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis DispensaryPress Release | 11/19/2024
With the New York cannabis market projected to surpass $5 billion by 2027, this acquisition positions CBDL for exponential revenue growth and expanded market dominance.
SCOTTSDALE, AZ / ACCESSWIRE / November 19, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneering force in the CBD and cannabis industries, is proud to announce the signing of a pivotal Letter of Intent (LOI) to acquire an interest in a cannabis dispensary located in New York. The dispensary, purchased from Market Wave Capital, LLC, is expected to generate $8 million in annual revenue once operational and marks a transformative moment in CBDL's journey toward industry dominance. Pending financing and state regulatory approvals, the dispensary is slated to open its doors within six months, ushering in a new chapter of accelerated growth and profitability.
A Game-Changing Move in a Booming Industry
The global marijuana dispensary market is on a meteoric rise, projected to grow at a compound annual growth rate (CAGR) of 25.5%, with revenues anticipated to surpass $73.6 billion by 2030. New York, a burgeoning hub for cannabis consumption and sales, presents unparalleled opportunities for growth, thanks to progressive legislation and a rapidly expanding consumer base.
"This acquisition is a monumental milestone for CBD Life Sciences and a testament to our aggressive growth strategy," said Lisa Nelson, President and CEO of CBDL. "The dispensary's location in New York positions us at the epicenter of one of the fastest-growing cannabis markets in the world. With projected revenues of $8 million annually, this venture is set to deliver significant value to our shareholders while opening new doors for expansion into adjacent markets."
Why This Matters for CBDL and Its Investors
The dispensary's strategic location in New York provides immediate access to a cannabis market projected to exceed $5 billion in annual sales by 2027. CBDL is seizing this opportunity at a critical juncture in the industry's evolution, aligning itself with the broader movement toward cannabis legalization and normalization.
For investors, this development underscores the company's ability to execute high-impact initiatives while navigating a highly competitive and regulated market. The acquisition not only bolsters CBDL's revenue potential but also establishes a foundation for future ventures in high-demand sectors, including recreational, medical, and hybrid cannabis markets.
Furthermore, the dispensary is expected to serve as a gateway for CBDL to introduce its own product lines into a retail setting, creating cross-promotional opportunities and fostering brand loyalty among a rapidly growing customer base.
Revenue, Growth, and a Vision for the Future
With potential revenues of $8 million annually, this acquisition is a significant leap forward for CBDL's financial profile. Beyond the immediate economic impact, this strategic move sets the stage for:
Market Diversification: The dispensary adds a robust revenue stream, complementing CBDL's existing portfolio of CBD products.
Future Expansion: Establishing a foothold in New York lays the groundwork for scaling operations to other states as cannabis legalization continues to gain momentum.
Enhanced Shareholder Value: The dispensary's profitability will drive returns for current shareholders while making CBDL an attractive investment for new stakeholders.
Strategic Significance
The acquisition reflects CBDL's forward-thinking approach to growth, as the company positions itself at the intersection of opportunity and innovation. By tapping into the New York cannabis market, CBDL is not just diversifying its portfolio but also creating synergies between its dispensary operations and its existing product lines, including pain creams, nano CBD coffee creamers, and more.
Additionally, the dispensary aligns with CBDL's mission to provide high-quality cannabis solutions while embracing consumer trends and regulatory changes. This move reinforces CBDL's standing as a company that is not only thriving in the present but also building for the future.
A Call to Shareholders and Future Investors
"This is only the beginning," added Nelson. "CBDL's strategic direction is clear: growth, innovation, and value creation. The dispensary will act as a springboard for broader ventures, and we are just getting started in leveraging the opportunities this industry offers."
CBDL invites shareholders and prospective investors to join us on this journey as we solidify our position as a leader in the cannabis and CBD industries. This acquisition underscores our commitment to seizing high-value opportunities and delivering long-term value to our shareholders. More updates to come!
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and cannabis industries, with a mission to enhance lives through premium-quality products and groundbreaking market strategies. The company's diverse portfolio and forward-thinking initiatives position it as a dynamic force in one of the most exciting and fast-growing industries in the world.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Closes-on-LOI-for-Potential-8-Million-Revenue-Cannabis-Dispensary?id=459587
Chartmaster
1 주 전
CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD WinePress Release | 11/13/2024
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.
SCOTTSDALE, AZ / ACCESSWIRE / November 13, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneer in the CBD wellness industry, is thrilled to announce its application for a beer and liquor license, paving the way for its entry into the CBD-infused wine market. This groundbreaking initiative is set to diversify the company's offerings and tap into one of the fastest-growing segments in the cannabis and alcohol industries.
Market Opportunity and Revenue Potential
The global cannabis beverage market is flourishing, with a valuation of $1.16 billion in 2023, projected to soar at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2030. In the U.S. alone, the CBD-infused beverage market is expected to exceed $1.4 billion by 2023, demonstrating an enormous demand for innovative, wellness-focused alcohol alternatives.
The broader cannabis beverage market, including CBD products, is estimated to grow from $4.55 billion in 2021 to a staggering $38.64 billion by 2030, with a CAGR of 27.1%. This trajectory highlights the lucrative potential of CBD-infused wine as an attractive investment and revenue driver for CBDL.
CBDL's Strategic Position
This move into the CBD wine market comes on the heels of a remarkable 1,744% revenue increase for CBD Life Sciences Inc. since February 2024. This growth reflects the company's ability to execute its strategic initiatives and meet consumer demand for premium CBD products effectively. With its beer and liquor license application in process, CBDL is poised to disrupt the wellness and alcohol sectors, further enhancing shareholder value.
"Applying for a beer and liquor license is a monumental milestone for our company," stated Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are seizing an opportunity to enter an untapped space that bridges the relaxation of wine with the health benefits of CBD. This initiative represents a massive growth opportunity for CBDL, with the potential to create entirely new revenue streams."
The Rise of CBD-Infused Beverages
CBD-infused beverages are rapidly becoming a preferred choice for consumers seeking alternative, functional drinks that support relaxation and well-being without the psychoactive effects of THC. According to market research, more than 50% of consumers in the U.S. have expressed interest in trying CBD beverages, including wines, which offer a sophisticated and wellness-oriented drinking experience.
By leveraging its expertise in CBD product formulation, CBDL plans to launch a premium CBD wine line that combines high-quality ingredients with advanced nanotechnology to enhance bioavailability. The product will cater to a growing demographic seeking healthier, holistic lifestyle options.
What This Means for Investors
The introduction of CBD-infused wines represents a bold leap forward for CBDL. Industry analysts estimate that cannabis beverages, including CBD-infused options, could account for up to 20% of the overall cannabis market by 2030. This shift could translate into billions of dollars in revenue, solidifying CBDL's leadership in the wellness and CBD industries.
With a focus on premium product innovation, distribution partnerships, and regulatory compliance, CBDL is positioning itself as a dominant player in this burgeoning market. This initiative also lays the groundwork for future expansion into other CBD alcohol categories, such as spirits, seltzers, and beers, amplifying the company's growth potential.
Consumer and Industry Impact
CBDL's foray into the CBD wine market is expected to resonate strongly with millennials and health-conscious consumers who value authenticity, wellness, and quality in their beverage choices. This new product line will provide consumers with a unique way to enjoy CBD while enhancing their social and relaxation experiences.
Furthermore, CBD-infused alcohol represents a game-changing opportunity to redefine the wine industry by introducing a wellness-centric alternative to traditional alcoholic beverages. CBDL aims to set a new standard of excellence with its commitment to innovation and quality.
Looking Ahead
CBD Life Sciences Inc. will provide updates on beer and liquor clients such as restaurants, bars, liquor stores and product launch timeline as milestones are achieved. Shareholders can look forward to seeing this transformative initiative come to life in the months ahead.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a cutting-edge leader in the CBD and wellness industry, offering a diverse range of innovative products designed to enhance consumer health and well-being. From CBD-infused creams to cutting-edge beverages, CBDL continues to push the boundaries of what is possible in the CBD space.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Applies-for-Beer--Liquor-License-to-Sell-CBD-Wine?id=458899
AveragePenny
1 주 전
$CBDL CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine
https://www.accesswire.com/941997/cbd-life-sciences-inc-cbdl-applies-for-beer-liquor-license-to-sell-cbd-wine
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.
SCOTTSDALE, AZ / ACCESSWIRE / November 13, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneer in the CBD wellness industry, is thrilled to announce its application for a beer and liquor license, paving the way for its entry into the CBD-infused wine market. This groundbreaking initiative is set to diversify the company's offerings and tap into one of the fastest-growing segments in the cannabis and alcohol industries.
Market Opportunity and Revenue Potential
The global cannabis beverage market is flourishing, with a valuation of $1.16 billion in 2023, projected to soar at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2030. In the U.S. alone, the CBD-infused beverage market is expected to exceed $1.4 billion by 2023, demonstrating an enormous demand for innovative, wellness-focused alcohol alternatives.
The broader cannabis beverage market, including CBD products, is estimated to grow from $4.55 billion in 2021 to a staggering $38.64 billion by 2030, with a CAGR of 27.1%. This trajectory highlights the lucrative potential of CBD-infused wine as an attractive investment and revenue driver for CBDL.
CBDL's Strategic Position
This move into the CBD wine market comes on the heels of a remarkable 1,744% revenue increase for CBD Life Sciences Inc. since February 2024. This growth reflects the company's ability to execute its strategic initiatives and meet consumer demand for premium CBD products effectively. With its beer and liquor license application in process, CBDL is poised to disrupt the wellness and alcohol sectors, further enhancing shareholder value.
"Applying for a beer and liquor license is a monumental milestone for our company," stated Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are seizing an opportunity to enter an untapped space that bridges the relaxation of wine with the health benefits of CBD. This initiative represents a massive growth opportunity for CBDL, with the potential to create entirely new revenue streams."
The Rise of CBD-Infused Beverages
CBD-infused beverages are rapidly becoming a preferred choice for consumers seeking alternative, functional drinks that support relaxation and well-being without the psychoactive effects of THC. According to market research, more than 50% of consumers in the U.S. have expressed interest in trying CBD beverages, including wines, which offer a sophisticated and wellness-oriented drinking experience.
By leveraging its expertise in CBD product formulation, CBDL plans to launch a premium CBD wine line that combines high-quality ingredients with advanced nanotechnology to enhance bioavailability. The product will cater to a growing demographic seeking healthier, holistic lifestyle options.
What This Means for Investors
The introduction of CBD-infused wines represents a bold leap forward for CBDL. Industry analysts estimate that cannabis beverages, including CBD-infused options, could account for up to 20% of the overall cannabis market by 2030. This shift could translate into billions of dollars in revenue, solidifying CBDL's leadership in the wellness and CBD industries.
With a focus on premium product innovation, distribution partnerships, and regulatory compliance, CBDL is positioning itself as a dominant player in this burgeoning market. This initiative also lays the groundwork for future expansion into other CBD alcohol categories, such as spirits, seltzers, and beers, amplifying the company's growth potential.
Consumer and Industry Impact
CBDL's foray into the CBD wine market is expected to resonate strongly with millennials and health-conscious consumers who value authenticity, wellness, and quality in their beverage choices. This new product line will provide consumers with a unique way to enjoy CBD while enhancing their social and relaxation experiences.
Furthermore, CBD-infused alcohol represents a game-changing opportunity to redefine the wine industry by introducing a wellness-centric alternative to traditional alcoholic beverages. CBDL aims to set a new standard of excellence with its commitment to innovation and quality.
Looking Ahead
CBD Life Sciences Inc. will provide updates on beer and liquor clients such as restaurants, bars, liquor stores and product launch timeline as milestones are achieved. Shareholders can look forward to seeing this transformative initiative come to life in the months ahead.
AveragePenny
2 주 전
$CBDL CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling
https://www.accesswire.com/939772/cbd-life-sciences-inc-cbdl-positioned-for-unmatched-growth-as-trump-welcomes-weed-legalization-and-federal-rescheduling
The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD 57.18 billion in 2023 to USD 444.34 billion by 2030, exhibiting a CAGR of 34.03% during the forecast period. North America dominated the global market with a share of 81.79% in 2022.
SCOTTSDALE, AZ / ACCESSWIRE / November 7, 2024 / With Former President Donald Trump's recent support for cannabis legalization in key U.S. states and calls to reclassify cannabis as a Schedule III drug, CBD Life Sciences, Inc. (OTC PINK:CBDL) is primed to accelerate its growth in the rapidly expanding cannabis and CBD market. This evolving regulatory environment is expected to unlock powerful revenue streams for CBDL, giving the company a strong competitive edge in an industry poised to reach unprecedented heights.
Major Market Opportunity: Riding the $100 Billion Wave
The U.S. cannabis market is projected to exceed $100 billion by 2030, fueled by widespread voter and legislative support. Trump's endorsement, including a personal commitment to vote "yes" on Florida's Amendment 3 to legalize recreational cannabis, signals bipartisan momentum for cannabis acceptance-a shift that could propel federal rescheduling and facilitate financial growth opportunities across the industry. As cannabis becomes more accessible, CBDL is strategically positioned to deliver innovative products that appeal to a broad consumer base, from wellness enthusiasts to medical patients.
CEO Lisa Nelson: "CBDL Ready to Capture Expansive Market Growth"
"For CBDL, this is a historic moment particularly as the company is currently in a Letter of Intent (LOI) with a cannabis dispensary, positioning itself to capitalize on the growing wave of cannabis legalization." says CEO Lisa Nelson. "With Trump having such significant support from both the public and key political leaders, the market potential is staggering. CBDL's strategic growth plan is designed to capture both the economic impact of increased accessibility and the opportunity to reach millions of new customers nationwide." This moment is especially historic as CBDL is currently in the middle of a Letter of Intent (LOI) with a cannabis dispensary, which aligns perfectly with this new wave of support for cannabis legalization."
CBDL's approach includes product innovation focused on high-quality CBD and cannabis-infused offerings tailored to meet the diverse needs of consumers. As more states pass cannabis-friendly laws, CBDL's distribution channels will expand, enabling the company to maximize its reach in high-demand markets and set new revenue records.
Unlocking Financial Pathways and Reducing Market Barriers
Rescheduling cannabis would not only open more avenues for scientific research but also allow CBD companies like CBDL to benefit from traditional financial and banking services. This anticipated regulatory easing means lower costs, streamlined operations, and increased scalability for CBDL-each of which has a direct impact on shareholder value and revenue growth. With a supportive regulatory environment, CBDL is expected to experience accelerated revenue increases, while establishing a reputation as a leader in research-backed, health-focused cannabis products.
Growing Market Support and Consumer Demand
CBDL's market expansion is also driven by strong consumer support: a recent Pew Research survey revealed that 88% of Americans favor cannabis legalization for either medical or recreational use, with 42% seeing it as a step toward a fairer criminal justice system. This shifting public opinion reflects a robust and growing market, allowing CBDL to target both new and existing consumers across recreational, medical, and wellness sectors. By leveraging this unprecedented demand, CBDL is well-positioned to introduce unique products to fulfill evolving consumer preferences and capitalize on the high-growth potential in this industry.
Link to Article: https://www.usatoday.com/story/news/politics/2024/11/05/donald-trump-marijuana-weed-cannabis-legalization-medical-recreational-election/75970501007/
Hot Features
프리미엄
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
koolmc
13 시간 전
firebag1
14 시간 전
Rainer
2 일 전
stealofadeal
5 일 전
MahinAgency
2 주 전
delerious1
2 주 전
SmellMyFinger
3 주 전
10thMountain
3 주 전
resx18
3 주 전
